Overview

• Medpace topped Q2 estimates with $603.3 million in revenue versus $538 million expected and delivered earnings of $3.10 per share against a $2.97 forecast.
• The company boosted its 2025 revenue outlook to $2.42–$2.52 billion from $2.14–$2.24 billion and set earnings guidance at $12.26–$13.04 per share.
• Pre-market trading on July 22 saw Medpace shares jump about 45% as investors responded to the stronger outlook.
• New business awards rose 12.6% year-over-year to $620.5 million in Q2, with a backlog of $2.87 billion supporting future growth.
• Medpace generated $148.5 million of operating cash flow and repurchased $518.5 million of stock in the quarter, with $826.3 million remaining under its buyback program.